Investor information

Company Overview

We are a global healthtech company providing medical services that maximize efficiency in prevention, diagnosis and precision medical treatment through innovative technologies. We are leaders in telemedicine and oncology treatment. We have a team of more than 2,000 professionals and are present in seven countries in Europe and Latin America. The company structures its activity around two main business areas. On the one hand, precision medicine, which includes diagnostic activities – telemedicine, nuclear medicine, pathological and molecular anatomy – and oncology treatment – medical oncology and advanced radiotherapy; and on the other hand, preventive medicine, dedicated to prevention and health promotion, from which we serve more than one million people through our network of more than 200 delegations. Atrys is the only listed company in the healthcare technology sector in Spain.

Corporate presentation
Learn more about us





















Shareholder structure: shareholder structure as at 25 January 2022 with 61,389,673 shares in issue

  • Free Float 37.6%
  • Excelsior Times 30.5%
  • Caser Group 5.2%
  • Global Porfolio Investments 6.3%
  • Equipo Directivo 9%
  • Inveready VC 5.1%
  • Onchena S.L. 6.2%

Share information:

2017
2018
2019
2020
2021
2022
No. of shares (thousands of shares)
11.153
20.430
22.695
33.596
61.390
73.643
P. at Period end
2,15
2,80
5,00
8,90
10,15
6,20
Maximum P.
2,15
3,32
6,05
9,00
11,25
10,85
Minimum P.
1,39
1,86
2,76
3,00
8,06
5,10
Market Capitalisation (EUR thousand)
23.979
57.205
113.475
299.005
623.105
456.587
Volume traded (thousands of shares)
260
772
3.798
7.099
11.185
6.714
Volume traded (EUR thousand)
1.071
10.339
19.961
48.501
104.467
48.011

Figures in thousands. Pro forma data including full year impact of acquisitions carried out. Source: BME

Analyst Reports

Adquisición relevante en Oncología (junio 2022): La compra del 100% de Bienzobas Salud

SEE PDF

Renta 4 Banco (enero 2023): Despidiendo 2022 con mucha salud

SEE PDF

Informe de análisis Banco Sabadell (enero 2022) Precio Objetivo: 12,50 EUR

SEE PDF

Informe GVC Gaesco (enero 2023)

SEE PDF

Rating Reports

Axesor Report March 2021

SEE PDF

Axesor Report June 2020

SEE PDF

Would you like to get in touch with the Investor Relations department?

Tell us how we can help you